Sanofi US
Cambridge
Massachusetts
United States
212 articles about Sanofi US
-
The FDA has approved Regeneron and Sanofi’s Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, making it the first drug approved for this indication.
-
Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
9/27/2022
Scribe Therapeutics Inc. today announced a strategic collaboration with Sanofi for the use of Scribe’s CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.
-
Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.
-
The FDA might only have two PDUFA dates on the calendar this week, but all eyes in the neurodegenerative disease community will be on the first one: Amylyx's AMX0035 for ALS.
-
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
9/15/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published positive results from a Phase 3 Dupixent® (dupilumab) trial in children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis.
-
The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.
-
Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia A
8/30/2022
The U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for efanesoctocog alfa for the treatment of hemophilia A, a rare and life-threatening bleeding disorder.
-
Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report
8/26/2022
The Centers for Disease Control and Prevention (CDC) has published the updated Advisory Committee on Immunization Practices (ACIP) guidance granting preferential recommendation for specific flu vaccines in people age 65+.
-
Cases of monkeypox infections reported in the latest viral outbreak have surpassed 14,000 in the U.S., according to the CDC. Some scientists believe the outbreak was predictable.
-
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns one of the two approved vaccines, may no longer be able to keep up.
-
Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations
8/12/2022
Amid signs that a more severe influenza season is approaching in the US, a panel of public health leaders urged that people get vaccinated in preparation for the upcoming influenza season and warned that patients in high-risk populations tend to suffer significant flu-related health disparities.3
-
The makers of ranitidine-based products, such as Sanofi, GSK and Haleon, are reeling from lawsuits related to carcinogenic contamination that could result in billions of dollars in damages.
-
Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare
8/3/2022
Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.
-
The measures will allow San Francisco and New York to coordinate efforts across different agencies and raise the public's awareness to curb the spread of monkeypox.
-
Sanofi released its second quarter financial report just two days after it announced its new diversity initiative with HBCU Howard University. Plus: Up-and-coming eczema biologics to shake Dupixent's foothold
-
Sanofi partners with Howard University in an unprecedented pharmacy fellowship program
7/26/2022
As part of its ongoing efforts to address disparities in underrepresented communities, Sanofi has announced a collaboration with Howard University College of Pharmacy for a two-year post-professional Doctorate in Pharmacy fellowship program.
-
Sanofi has terminated a development agreement with Regulus in Alport syndrome, while Merck reaches the point of futility in a Phase III colorectal cancer trial.
-
Sanofi, Certara, Pfizer and Thermo Fisher are facing hiring challenges head-on with a common strategy: upskilling programs. They use these programs to fill open roles while training and retaining existing talent.
-
Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.
-
Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.